Plaque Psoriasis: Causes, Triggers & Why Conventional Treatments Are Failing in 2026

35+ Years of Clinical Research  ·  Plant-Based EU-Regulated Formulas  ·  Certified Treatment Centers in 15+ U.S. States

Kapyderm USA  ·  Skin Conditions  ·  Clinical Guide — July 2026

Plaque Psoriasis: Causes, Triggers
& Why Conventional Treatments
Are Failing in 2026

nearly 9 million Americans live with psoriasis. Most are managing it with steroids that cause skin atrophy, coal tar that stains and irritates, or biologics costing $25,000+ per year that suppress the entire immune system. In 2026, the science points to a better approach — and the gut-skin axis research explains why.

MA

Reviewed by: Marlen Arita — Master in Dermotricology · Kapyderm USA Clinical Director
Published July 9, 2026  ·  22 min read

Home › Blog › Plaque Psoriasis — Complete 2026 Clinical Guide

Quick answer

Plaque psoriasis is a chronic autoimmune inflammatory skin disease driven by dysregulation of the IL-23/Th17 immune axis — causing skin cell turnover to accelerate from 28 days to 3–5 days, forming thick, scaly plaques most commonly on the elbows, knees, scalp, and lower back. It affects nearly 9 million Americans and 125 million people worldwide. The conventional treatment path — topical steroids, coal tar, and biologics — carries serious long-term liabilities that a growing number of patients are no longer willing to accept. The 2026 research on the gut-skin axis confirms that psoriasis is also an inside-out condition, and that no topical treatment alone can address the systemic inflammatory drivers. The Kapyderm Dermotricology protocol addresses psoriasis through a 7-component plant-based system targeting both the skin barrier and the internal inflammatory environment — without steroids, without coal tar, and without a prescription.

In this article

1. What plaque psoriasis actually is — the immune mechanism
2. Who gets psoriasis — prevalence and risk factors
3. Types of psoriasis — identification guide
4. Triggers — what causes flares
5. Why conventional treatments are failing in 2026
6. The topical steroid withdrawal crisis
7. The gut-skin axis — 2026 research on psoriasis
8. Psoriasis on skin of color
9. Treatment landscape — honest comparison
10. The Dermotricology plant-based protocol
11. Frequently asked questions

What Plaque Psoriasis Actually Is — The Immune Mechanism

Psoriasis is not a skin problem with an immune component. It is an immune disease that manifests on the skin. This distinction determines everything about how it should be treated — and why treating only the surface produces temporary results at best.

In healthy skin, the cell turnover cycle runs approximately 28 days — new cells generated in the basal layer migrate to the surface and shed in an orderly process. In plaque psoriasis, an overactive immune cascade driven by the IL-23/Th17 pathway accelerates this cycle to 3–5 days. New cells accumulate on the surface faster than they can shed, forming the raised, scaly plaques that define the condition. The inflammation that drives this process also causes the redness, heat, and itching that accompany plaques — and extends systemically, explaining psoriasis's well-documented associations with psoriatic arthritis, cardiovascular disease, and metabolic syndrome.[1]

The IL-23/Th17 axis — why this matters for treatment

The IL-23/Th17 immune pathway is the central driver of plaque psoriasis. IL-23 activates Th17 cells, which release IL-17 — a cytokine that triggers keratinocyte hyperproliferation and chronic skin inflammation. The most effective pharmaceutical interventions in 2026 (biologics like secukinumab, ixekizumab, risankizumab) work by blocking IL-17 or IL-23 specifically. This is also the pathway that botanical anti-inflammatory support — working systemically to reduce the chronic inflammatory load — can influence through different, non-pharmaceutical mechanisms. The goal is not to suppress the entire immune system, but to reduce the inflammatory cascade that triggers the IL-23/Th17 dysregulation in the first place.

---

Who Gets Psoriasis — Prevalence and Risk Factors

8M Americans currently living with psoriasis — and 125 million people worldwide. About 80–90% have plaque psoriasis specifically[2]

$25K+ estimated annual cost per patient for biologic therapy — the current clinical gold standard for moderate-to-severe psoriasis, and the reason most patients are actively looking for alternatives[3]

30% of psoriasis patients develop psoriatic arthritis — making systemic treatment essential and surface-only approaches insufficient for long-term management[1]

Psoriasis typically first appears between ages 15 and 35, though it can develop at any age — including in children and older adults. It affects all skin tones, all genders, and all ethnicities equally in prevalence, though its presentation varies significantly across skin types. A genetic component is established: HLA-C*06:02 shows the strongest association, particularly for early-onset disease. But genetics alone don't trigger psoriasis — environmental exposures, immune dysregulation, stress responses, and increasingly, gut microbiome health are all confirmed co-factors.

---

Types of Psoriasis — Identification Guide

Plaque psoriasis accounts for 80–90% of all psoriasis cases, but understanding the full spectrum helps identify when you're dealing with psoriasis versus another skin condition — and which areas of the body are affected.

Most Common — 80–90%

Plaque Psoriasis (Psoriasis Vulgaris)

Raised, inflamed, scaly patches — typically on the elbows, knees, lower back, and scalp. Plaques are red/pink with silvery scales on lighter skin; darker, thicker purple or brown patches on skin of color. Can be localized or affect large body surface areas simultaneously.

Scalp

Scalp Psoriasis

Present in approximately half of all psoriasis patients — flaking, scaling, and inflammation confined to or extending beyond the hairline. Often co-presents with body plaque psoriasis. Requires different formulations than body treatment — see our dedicated scalp psoriasis guide.

Inverse

Inverse (Flexural) Psoriasis

Smooth, shiny, non-scaly plaques in skin folds — armpits, groin, under breasts, genital area. Lacks the typical scale because friction and moisture in these areas prevent buildup. Often misdiagnosed as fungal infection. Particularly sensitive to topical treatments; steroid use in skin folds is more concerning due to higher absorption.

Guttate

Guttate Psoriasis

Small, drop-shaped lesions that appear suddenly across the trunk and limbs — often triggered by a streptococcal (strep) throat infection, particularly in children and young adults. May resolve on its own within a few weeks or develop into chronic plaque psoriasis. One of the clearest examples of how infection triggers the IL-23/Th17 cascade.

Pustular

Pustular Psoriasis

Pus-filled blisters surrounded by red skin — not infectious, but requires clinical evaluation. Localized forms (palmoplantar) appear on the palms and soles. Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening emergency. Any sudden widespread pustular eruption requires immediate medical attention.

Erythrodermic

Erythrodermic Psoriasis

A severe, potentially life-threatening form covering most of the total body surface area with confluent erythema, scaling, and exfoliation. Medical emergency — requires immediate clinical care. Rarely develops without prior psoriasis history and is often triggered by sudden medication discontinuation or infection.

---

Triggers — What Causes Psoriasis Flares

Psoriasis is not continuously active — it flares when specific triggers activate the IL-23/Th17 immune cascade against a background of genetic susceptibility. Identifying and managing triggers is the most underutilized tool in psoriasis management, and frequently the factor most ignored in conventional pharmaceutical approaches.

✦

Psychological stress — The most consistently reported trigger. Stress activates the HPA axis and triggers cortisol elevation and substance P release — both of which directly amplify the inflammatory cascade driving plaque formation. Managing stress is not optional in psoriasis care; it is clinically essential.

✦

Medications — Beta-blockers, lithium, calcium channel blockers, ACE inhibitors, NSAIDs, anti-malarial drugs, and checkpoint inhibitors are all documented psoriasis triggers.[4] If you started a new medication and experienced a psoriasis flare within weeks, this is the clinical connection to investigate with your physician.

✦

Skin injuries — the Koebner phenomenon — Cuts, scrapes, sunburn, insect bites, surgical incisions, and tattoos can trigger new psoriasis plaques in areas of skin injury. Approximately 25–50% of psoriasis patients experience this phenomenon. It is one of the most important reasons to protect psoriatic skin from physical trauma.

✦

Infections — especially streptococcal — Strep throat is a well-documented trigger, particularly for guttate psoriasis in children and young adults. Any systemic infection that activates the immune system can precipitate a psoriasis flare. COVID-19 has been documented as a trigger in some patients.

✦

Alcohol and smoking — Both are independent risk factors for psoriasis development and flare severity. Alcohol impairs immune regulation and increases systemic inflammation. Smoking is particularly associated with palmoplantar pustular psoriasis and is one of the strongest modifiable risk factors for psoriasis overall.

✦

Diet and metabolic factors — Obesity is a documented psoriasis trigger and exacerbating factor — adipose tissue produces pro-inflammatory cytokines that amplify the IL-23/Th17 cascade. High-glycemic diets, alcohol, and Western dietary patterns are associated with higher psoriasis severity. Anti-inflammatory dietary patterns — omega-3 fatty acids, plant-based foods, fiber — are associated with reduced flare frequency.

✦

Weather and environmental factors — A 2021 JMIR Dermatology review confirmed that psoriasis searches are elevated in late winter and early spring, correlating with cold, dry conditions that worsen barrier function and reduce UV exposure. Air pollution (PM2.5 particulate matter) was documented in a 2025 study as synergistically increasing psoriasis risk alongside genetic predisposition.[5]

---

Why Conventional Treatments Are Failing in 2026 Critical

The 2026 psoriasis treatment landscape is technically more advanced than ever — 12 biologics are now approved to treat psoriasis, IL-17 and IL-23 inhibitors achieve PASI 90 clearance in clinical trials, and new PDE-4 inhibitors offer steroid-free topical options. For the patients who can access these treatments and tolerate their risk profiles, this represents genuine progress.

But the gap between what clinical trials achieve and what patients experience in real-world long-term management is the story most psoriasis content doesn't tell. Here is what is actually failing:

Topical Corticosteroids — The Most Widely Used, Most Misused Treatment

Topical steroids remain the first-line treatment for mild-to-moderate psoriasis globally, and they work — in the short term. The problems emerge with the long-term use that psoriasis's chronic nature demands. Tachyphylaxis — the skin's acquired diminished response to repeated steroid use — means that progressively higher potency is needed to achieve the same effect.[6] Side effects of long-term use include skin atrophy, telangiectasia, striae, and systemic absorption that in rare cases produces Cushing-like syndrome.[7] The result is a cycle of dependency that worsens over time.

Coal Tar — The 100-Year-Old Treatment Still Being Prescribed

Coal tar is one of the oldest psoriasis treatments in existence. It reduces scaling and slows cell turnover. It also stains everything it contacts, smells strongly, causes skin irritation and photosensitivity, and carries a long-standing carcinogenic concern — coal tar contains polycyclic aromatic hydrocarbons that are classified as Group 1 carcinogens by the IARC. While the clinical consensus is that therapeutic coal tar at regulated concentrations is acceptable for short-term use, many patients with chronic psoriasis are using it for years. A steroid-free, coal tar-free alternative with 35+ years of EU-regulated clinical evidence is not a luxury for these patients — it is a clinically rational upgrade.

Biologics — Effective but Inaccessible for Most

For moderate-to-severe psoriasis, biologics targeting IL-17 and IL-23 are genuinely transformative. But at $15,000–$25,000+ per year before insurance, with injection schedules and monitoring requirements, and with black box warnings for infection risk and potential cancer risk with some agents, biologics are not a population-level solution. Patients fear the term "biological agents" itself — a documented phenomenon in the clinical literature, where patients express concern about long-term biologic dependency and infection risk.[8]

The 2026 paradigm shift

In 2026, "consumers and medical experts alike are embracing clinical botanical solutions — formulations that combine the therapeutic power of plant-based ingredients with the rigorous standards of modern dermatological testing." The National Psoriasis Foundation itself recommends choosing non-irritating over-the-counter options as crucial to supporting daily psoriatic skin health without triggering inflammatory responses. This is not fringe thinking — it is the direction the entire dermatology field is moving for long-term management of chronic skin conditions.

---

The Topical Steroid Withdrawal Crisis 2026

Topical Steroid Withdrawal (TSW) is an adverse effect of prolonged topical corticosteroid use that is rising in clinical awareness — and in patient harm. It occurs when the skin, having adapted to steroid-mediated suppression of inflammation, experiences a severe rebound when steroids are discontinued.

In psoriasis patients, TSW is particularly concerning because the chronic nature of the condition creates pressure toward indefinite steroid use. Symptoms of TSW include burning pain, severe erythema, diffuse desquamation, and skin edema — often significantly worse than the original psoriasis. A January 2026 review in the Sage Journals confirmed TSW remains under-recognized despite rising awareness, with symptoms overlapping multiple skin conditions that complicate diagnosis.[9]

The clinical implication is significant: patients who have been using topical steroids for psoriasis long-term cannot simply stop using them and transition to a botanical protocol — they may need a medically supervised taper. This is one of the most important reasons to establish a steroid-free botanical protocol earlier rather than later, and to work with a certified Dermotricology practitioner when transitioning away from long-term steroid use.

---

The Gut-Skin Axis — What 2026 Research Says About Psoriasis New

The connection between gut health and psoriasis severity is now one of the most active research areas in dermatology — and the 2025–2026 evidence is among the most significant yet.

January 2026 — PMC review on the gut-brain-skin axis

A comprehensive January 2026 review in PMC confirmed that gut microbiome dysbiosis serves as a primary pathophysiological factor in psoriasis through the gut-brain-skin axis. Psoriasis patients consistently show reduced microbial diversity, lower levels of SCFA-producing bacteria (Faecalibacterium and Akkermansia), and increased pro-inflammatory bacteria compared to healthy controls.[10] The review evaluated mechanisms linking gut microbiome dysbiosis to psoriasis-associated neuropsychiatric comorbidities including depression and anxiety — conditions that affect a significant proportion of psoriasis patients and are rarely addressed by topical-only treatment approaches.

The mechanism: intestinal barrier disruption — "leaky gut" — allows inflammatory compounds to enter systemic circulation. Elevated serum biomarkers including Claudin-3, TMAO, and intestinal fatty acid binding protein are positively correlated with psoriasis severity, confirming that compromised gut barrier function directly contributes to skin inflammation severity.[11]

A 2025 systematic review and meta-analysis in BMC Immunology — covering randomized controlled trials through 2024 — confirmed that gut microbiota-targeted interventions produce measurable improvements in psoriasis severity scores and inflammatory markers.[12] This is the evidence base for why the Kapyderm psoriasis protocol includes dePure and Revital as internal botanical components — not as optional supplements, but as clinically rationale-supported essential components of a comprehensive psoriasis approach.

---

Psoriasis on Skin of Color — A Critically Underserved Population

Psoriasis is equally prevalent across skin tones — but its clinical presentation, diagnosis, and treatment experience differ significantly for patients with darker complexions, and the dermatological literature has historically underserved this population.

How psoriasis looks different on skin of color: On darker skin, plaques typically appear purple, grayish, or dark brown rather than the classic red/pink of textbook descriptions. Scaling may appear ashy. The contrast between affected and unaffected skin is different, making standard severity assessments (PASI scoring) less accurate for darker skin tones. These presentation differences lead to frequent misdiagnosis and delayed treatment.

Post-inflammatory hyperpigmentation (PIH): After plaques clear, dark spots remain — sometimes for months or years. PIH is significantly more pronounced and more persistent on melanin-rich skin. This means the cosmetic impact of psoriasis on patients with darker skin continues long after the active inflammation has resolved — and treatment choices that avoid irritation and steroid-induced pigmentation changes are more critical for this population.

Why steroid-free is especially important for skin of color

High-potency topical steroids are more concerning for patients with darker skin tones for two reasons: they can cause hypopigmentation (lightening of melanin-rich skin) in areas of application, and the risk of skin atrophy is compounded by PIH from the underlying psoriasis plaques. A plant-based, steroid-free botanical protocol eliminates these concerns entirely — making it a clinically superior choice for psoriasis management in patients with skin of color.

---

The 2026 Treatment Landscape — Honest Assessment

Treatment	Mechanism	Evidence	Real-World Limitations
Topical Corticosteroids	Suppress local inflammation and cell proliferation	Effective short-term — first-line globally	Tachyphylaxis; skin atrophy; systemic absorption; TSW on discontinuation; not for long-term use
Coal Tar	Slows cell turnover; anti-inflammatory	100+ years of use; modest efficacy for scaling	Carcinogenic PAHs (Group 1 IARC); staining; odor; skin irritation; photosensitivity; poor patient compliance
Vitamin D Analogues (calcipotriol)	Slow skin cell growth; reduce inflammation	Good evidence; effective long-term topical; often combined with steroids	Skin irritation; facial use limited; hypercalcemia risk if used on large areas; slow onset
Roflumilast (Zoryve) — Topical PDE-4 Inhibitor	PDE-4 inhibition; steroid-free anti-inflammatory	FDA-approved, steroid-free; steroid-free; strong evidence; once daily	Prescription only; access/cost; relatively new; long-term data still accumulating
UV Phototherapy (UVB/PUVA)	Ultraviolet B light slows skin cell turnover; reduces inflammation	Strong evidence; effective for moderate-severe; steroid-free	Requires 2–3 clinic visits per week for 10–12 weeks; cumulative UV exposure concerns; not accessible to most patients; does not address internal drivers
Methotrexate (Oral/Injection)	Immunosuppressant — reduces cell proliferation	Decades of evidence; moderate-severe psoriasis; globally accessible	Liver toxicity; pulmonary risk; monthly bloodwork; teratogenic; not safe in pregnancy
Biologics (IL-17/IL-23 inhibitors)	Target specific immune pathway cytokines — most precise intervention available	Highest clinical clearance rates; PASI 90+ achievable; transformative for severe disease	$15,000–$25,000+/year; injection/infusion; infection risk black box; long-term dependency; not accessible to most patients
Kapyderm Body Psoriasis Home Treatment	Multi-driver botanical system: plaque dissolution + microbiome rebalancing + barrier repair + internal systemic detox	Plant-based EU-regulated system for mild-moderate psoriasis or complement to clinical treatment	No steroids · No coal tar · No prescription · No carcinogens · Appropriate for long-term use · All skin tones

---

The Dermotricology Plant-Based Protocol for Body Psoriasis

The Kapyderm approach to plaque psoriasis follows the same foundational principle applied across every Dermotricology condition: treat all drivers simultaneously, not sequentially. The 7-component system addresses plaque dissolution topically, microbiome rebalancing of the skin surface, barrier repair, and systemic internal detox — creating a comprehensive protocol that no single topical can replicate.

1

Normalizing Base Cleanser Topical · Morning & Evening Therapeutic botanical cleanser that purifies affected skin, removes surface scale buildup and oxidized debris, and clears the skin surface for maximum penetration of active topical formulas. Critical for body psoriasis — scale accumulation blocks every subsequent product from reaching target tissue. Formulated for multi-zone use including elbows, knees, lower back, and trunk.

2

KS115 Tonic Topical · Applied to affected areas Targeted botanical tonic addressing the hyperkeratinization driver of psoriasis — excess skin cell accumulation that forms the characteristic plaque. KS115 supports the normalization of skin cell turnover speed, promoting more orderly shedding and reducing the buildup rate that creates visible plaques. Applied directly to affected body zones.

3

K1 Tonic Topical · Applied to affected areas Botanical tonic delivering targeted anti-inflammatory and barrier-supporting actives to psoriatic skin. Works synergistically with KS115 to address both the inflammatory cascade driving plaque formation and the barrier dysfunction that allows the inflammatory cycle to perpetuate. Particularly effective for the thick, established plaques of chronic body psoriasis.

4

Special K Cream Topical · Applied to all affected zones The barrier restoration and therapeutic anchor of the topical protocol. A potent botanical cream that seals structural lipid gaps in psoriatic skin, delivers concentrated anti-inflammatory support, reduces the inflammatory signaling that drives cell hyperproliferation, and restores the hydrolipid film that psoriatic skin continuously loses. Compatible with all skin tones — does not cause pigmentation changes or skin atrophy.

5

Fungi-Activ Topical · Applied to active plaques Targeted botanical antimicrobial and antifungal formula applied directly to active psoriatic plaques. The skin microbiome dysbiosis that accompanies psoriasis — overgrowth of Malassezia and pathogenic bacteria in the altered skin environment of plaques — amplifies the inflammatory cascade. Fungi-Activ addresses this skin microbiome component that conventional topical steroids ignore entirely.

6

dePure Supplement Internal · 2 caps morning + 2 caps afternoon Artichoke, Boldo, Dandelion — botanical liver support and systemic detoxification formula addressing the internal inflammatory load that the gut-skin axis research confirms perpetuates psoriasis from within. A January 2026 review confirmed gut dysbiosis as a primary pathophysiological factor in psoriasis — elevated systemic inflammatory biomarkers correlate directly with psoriasis severity. This is the internal component no topical product can reach.

7

Revital Supplement Internal · Nightly Comprehensive nutritional support addressing the deficiencies that chronic psoriasis inflammation continuously depletes — and that conventional pharmaceutical approaches do not address. Taken nightly to support overnight cellular repair and immune regulation during the body's peak regenerative period. Supports the gut microbiome diversity that the 2026 research confirms is reduced in psoriasis patients.

Support included with every treatment

Every Kapyderm treatment system purchase includes two complimentary 20-minute video sessions with a certified Dermotricology specialist — to walk you through your protocol, answer your questions, and make sure you're applying each step correctly. You're never left to figure it out alone.

Not sure where to start, or want to talk through your skin before you buy? Book a free discovery call at cal.com/kapyderm →

Important — transitioning from long-term steroid use

If you have been using topical corticosteroids for psoriasis for an extended period and are considering transitioning to a steroid-free botanical protocol, do not stop steroids abruptly. TSW (Topical Steroid Withdrawal) is a real and clinically documented risk. Work with a certified Kapyderm Dermotricology practitioner or your dermatologist on a medically supervised taper plan before beginning the Kapyderm protocol. A certified center can guide this transition safely, monitoring skin response and adjusting the protocol accordingly.

---

Frequently Asked Questions

What causes plaque psoriasis?

Plaque psoriasis is driven by dysregulation of the IL-23/Th17 immune axis — causing the immune system to accelerate skin cell turnover from 28 days to 3–5 days. Dead skin cells accumulate forming characteristic plaques. Genetic susceptibility (HLA-C*06:02) creates predisposition, but environmental triggers including stress, infections, medications, diet, and gut microbiome dysbiosis activate the immune cascade. The 2026 research confirms that leaky gut and reduced microbial diversity directly contribute to systemic inflammatory load that drives and perpetuates psoriasis.

Why do steroid creams stop working for psoriasis?

Tachyphylaxis — an acquired diminished response to repeated steroid use — is a documented and common side effect of topical corticosteroids. The skin adapts to the steroid signal over time, requiring progressively higher potency for the same effect. Long-term use also causes skin atrophy, telangiectasia, and increased systemic absorption. When steroids are discontinued, rebound flares are common — often more severe than the original psoriasis. This cycle is why many patients are actively seeking steroid-free alternatives.

What is topical steroid withdrawal (TSW) and does it affect psoriasis patients?

TSW is an adverse effect of prolonged topical steroid use — characterized by burning pain, severe redness, skin edema, and widespread desquamation when steroids are discontinued. In psoriasis patients, the chronic nature of the condition creates pressure toward indefinite steroid use, making TSW a real and significant risk. A January 2026 clinical review confirmed TSW remains under-recognized. Patients transitioning to steroid-free botanical protocols after long-term steroid use should do so under clinical supervision with a medically supervised taper.

Does the gut affect psoriasis?

Yes — substantially. A January 2026 PMC review confirmed gut microbiome dysbiosis as a primary pathophysiological factor in psoriasis through the gut-brain-skin axis. Psoriasis patients show reduced microbial diversity and elevated gut-permeability biomarkers that correlate directly with psoriasis severity. A 2025 BMC Immunology meta-analysis confirmed that gut microbiota-targeted interventions improve psoriasis severity scores. The internal detox component of the Kapyderm protocol (dePure, Revital) directly addresses this dimension.

What does psoriasis look like on darker skin tones?

On skin of color, plaques appear darker and thicker — purple, grayish, or dark brown rather than the classic red/pink. This leads to frequent misdiagnosis. Post-inflammatory hyperpigmentation (dark spots after plaques clear) is more pronounced and persistent on melanin-rich skin. Steroid-free protocols are particularly important for patients with darker skin because high-potency steroids can cause hypopigmentation in treated areas, adding a second pigmentation concern alongside PSH from the psoriasis itself.

Is the Kapyderm body psoriasis treatment different from the scalp psoriasis treatment?

Yes — both in formulation and in the components included. The body psoriasis system is specifically designed for the elbows, knees, lower back, trunk, and other non-scalp zones — using KS115 and K1 Tonic for plaque dissolution and barrier repair appropriate for body skin thickness and surface area. The scalp psoriasis system uses different formulations suited to the follicular environment and scalp-specific conditions. Both include the internal detox components (dePure, Revital) as the systemic foundation of the protocol. See our dedicated scalp psoriasis guide for that treatment specifically.

Related Resources

01 Find a Certified Kapyderm Treatment Center near you → 02 Body Psoriasis Home Treatment — 7-Component Botanical System → 03 Psoriasis Treatment Overview — The Dermotricology Approach → 04 Scalp Psoriasis — Complete Clinical Guide →

Clinical References & Sources

1. Armstrong AW et al. Psoriasis. Nature Reviews Disease Primers, 2025. IL-23/Th17 axis; comorbidities; HLA-C*06:02; management strategies. nature.com — s41572-025-00630-5
2. National Psoriasis Foundation. About Psoriasis. nearly 9 million Americans; 80–90% plaque psoriasis; all skin types. psoriasis.org/about-psoriasis
3. Dermatology Times. 2025 Year in Review: Psoriasis. Biologic efficacy; IL-23 inhibitors; TYK2 inhibitors; treatment landscape. dermatologytimes.com
4. Qasem SF et al. Therapeutic Advancements in the Management of Psoriasis. Cureus, 2025 Feb. Medication triggers including lithium, beta-blockers, NSAIDs; corticosteroid tachyphylaxis. PMC11920851
5. AJMC. Top 5 Most-Read Psoriasis Content of 2025. Air pollution and genetic predisposition synergistically increase psoriasis risk. ajmc.com
6. Qasem SF et al. Therapeutic Advancements in the Management of Psoriasis. Cureus, 2025. Tachyphylaxis as common side effect of topical corticosteroids. PMC11920851
7. PMC Case Report. Iatrogenic Cushing's syndrome induced by topical steroid abuse in a patient with psoriasis. 2025. PMC12515825
8. PMC. Are there any concerns about the usage of biological agents in psoriasis? Patient trepidation about biologics; desire to discontinue; infection risk concerns. PMC11407340
9. Moon Y, Lio P. Therapeutic Update on Topical Steroid Withdrawal. Sage Journals, January 2026. TSW rising awareness; under-recognized; treatment options review. doi:10.1177/17103568251413232
10. PMC. Immunoprotective and neuroprotective properties of gut microbiome in psoriasis. Published June 2026 (accepted January 2026). Gut-brain-skin axis; SCFA-producing bacteria; microbial diversity reduction. PMC12816903
11. Frontiers in Microbiology. Psoriasis and gut microbes: research advances from mechanism to therapy. Published November 2025. Leaky gut; Claudin-3; TMAO biomarkers correlated with psoriasis severity. doi:10.3389/fmicb.2025.1711288
12. Zhu L et al. Efficacy and safety of gut microbiota-targeted therapy in patients with psoriasis: a systematic review and meta-analysis of randomized controlled trials. BMC Immunology, 2025. doi:10.1186/s12865-025-00747-y

All references are peer-reviewed publications or recognized clinical institutions. Last reviewed July 2026.

MA

Marlen Arita

Master in Dermotricology · Kapyderm USA Clinical Director

Marlen Arita is a certified Master in Dermotricology and clinical director of Kapyderm USA. This guide incorporates the most current 2025–2026 evidence on plaque psoriasis — including the January 2026 gut-brain-skin axis review, the TSW clinical update, the Nature Reviews Disease Primers psoriasis Primer (2025), and the 2025 AJMC Year in Review on psoriasis treatment advances.

7 Components. All Drivers.
No Steroids. No Coal Tar. No Prescription.

The Kapyderm Body Psoriasis Home Treatment addresses plaque dissolution, microbiome rebalancing, barrier repair, and internal systemic inflammation — simultaneously. Plant-based, EU-regulated, appropriate for all skin tones and long-term daily use. Every treatment system includes two complimentary 20-minute video sessions with a certified specialist.

Get the Body Psoriasis Treatment → Book a Free Discovery Call →

Prefer to talk to someone first? Book a discovery or consultation call at cal.com/kapyderm — or find a certified center.

Continue reading

Scalp Conditions

Scalp Psoriasis — Complete Clinical Guide & Plant-Based Treatment

Skin Conditions

Eczema & Atopic Dermatitis: Causes, TSW & Treatment — 2026 Clinical Guide

Skin Conditions

Acne: Causes, Types & Why Antibiotics Are Failing — 2026 Clinical Guide

Explore Kapyderm USA Body Psoriasis Treatment · Psoriasis Treatment Overview · Scalp Psoriasis Guide · Eczema Guide · Find a Certified Center · Free Consultation →